08:00 , Jan 14, 2013 |  BC Week In Review  |  Company News

ArmaGen management update

ArmaGen Technologies Inc. , Santa Monica, Calif.   Business: Neurology   Hired: James Callaway as president, CEO and a director, formerly president and CEO of Cebix Inc.  ...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Clinical News

Ersatta: Phase Ib/IIa data

Top-line data from 42 Type I diabetics with signs of peripheral neuropathy in the Phase IIa portion of a double-blind, U.S. Phase Ib/IIa trial showed that subcutaneous Ersatta significantly improved mean sural SNCV from baseline...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Company News

Cebix management update

Cebix Inc. , La Jolla, Calif.   Business: Endocrine/Metabolic   Hired: Joel Martin as president and CEO, formerly president and CEO of Altair Therapeutics Inc. , which an undisclosed company acquired  ...
07:00 , Oct 22, 2012 |  BC Week In Review  |  Financial News

Cebix completes venture financing

Cebix Inc. , La Jolla, Calif.   Business: Endocrine/Metabolic   Date completed: 10/17/12   Type: Venture financing   Raised: $21.3 million   Investors: InterWest Partners; Sofinnova Partners; Thomas, McNerney & Partners  ...
00:57 , Oct 18, 2012 |  BC Extra  |  Financial News

Cebix raises $21.3M, names Martin CEO

Cebix Inc. (La Jolla, Calif.) raised $21.3 million in a series B round and hired Joel Martin as president and CEO. Martin is formerly president and CEO of asthma company Altair Therapeutics Inc. , which...
07:00 , Jun 18, 2012 |  BC Week In Review  |  Clinical News

Ersatta: Phase Ib data

A double-blind, placebo-controlled, U.S. Phase Ib trial in 30 Type I diabetics showed that multiple doses of 0.3, 1 and 3.3 mg subcutaneous Ersatta were well tolerated with no serious adverse events reported. Data were...
07:00 , Jul 4, 2011 |  BC Week In Review  |  Clinical News

Cebix preclinical data

In a rat model of diabetic peripheral neuropathy, subcutaneous Ersatta led to a 4 m/sec reversal of sensory nerve conduction velocity impairment. The long-acting form of C-peptide is in Phase Ib testing to treat Type...
07:00 , Jun 20, 2011 |  BC Week In Review  |  Clinical News

Ersatta: Phase Ib started

Cebix began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate single and multiple subcutaneous injections of Ersatta in up to 60 Type I diabetics. Cebix Inc. , La Jolla, Calif.   Product: Ersatta (...